Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maze TherapeuticsMAZE +1.06%16 Debt-to-EBITDA is -0.67 as of Mar. 2026. GuruFocus rates MAZE with a GF Score™ of 16/100. The stock has 2 warning signs investors should review. Among 298 Biotechnology companies, Maze Therapeutics ranks worse than 335570.13% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Maze Therapeutics's Debt-to-EBITDA or its related term are showing as below:
MAZE'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.53 Med: -0.23 Max: 0.44
Current: -0.48
During the past 4 years, the highest Debt-to-EBITDA Ratio of Maze Therapeutics was 0.44. The lowest was -0.53. And the median was -0.23.
MAZE's Debt-to-EBITDA is ranked worse than 100% of 298
companies
in the Biotechnology industry
Industry Median: 1.23
vs MAZE: -0.48
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Maze Therapeutics Debt-to-EBITDA Related Terms
Maze Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Maze Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MAZE vs NTLA, RXRX, SEPN: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Maze Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maze Therapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maze Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Maze Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Maze Therapeutics (MAZE) has a Debt-to-EBITDA of -0.67 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Maze Therapeutics. According to the industry distribution chart, Maze Therapeutics ranks #999999 out of 298 companies in the Biotechnology industry.
Is Maze Therapeutics' Debt-to-EBITDA too high?
Maze Therapeutics' current Debt-to-EBITDA is -0.67. Based on the distribution chart, Maze Therapeutics ranks #999999 out of 298 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Maze Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Maze Therapeutics' Debt-to-EBITDA compare to NTLA and RXRX?
According to the Biotechnology industry distribution chart, Maze Therapeutics ranks #999999 out of 298 companies for Debt-to-EBITDA. This places Maze Therapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.23, based on 298 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Maze Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maze Therapeutics's current Debt-to-EBITDA is -0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maze Therapeutics stock overvalued right now?
Maze Therapeutics (MAZE) has a current Debt-to-EBITDA of -0.67. The current Debt-to-EBITDA is -0.67. Maze Therapeutics' overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Maze Therapeutics (MAZE), the current Debt-to-EBITDA is -0.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
16GF Score
Get the complete analysis for MAZE
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAZE has been successfully added to your 
